Contract manufacturing capacity tightens for sterile assembly

Contract manufacturers specialising in sterile assembly report high utilisation across European sites. Capacity for ISO class 7 cleanrooms, ethylene oxide sterilisation, and packaging validation is booked well ahead, and some suppliers have stopped accepting new programmes for the coming year. The constraint is sharpest for small batch sizes, where changeover time and cleaning validation dominate the cost calculation, and where a dedicated line is rarely justified.

The constraint is not only physical space. Qualified cleanroom operators and sterilisation specialists are scarce, and expanding a line requires environmental qualification, process validation, and often a new regulatory notification. Those steps take a year or more even when the capital is available, which means that capacity announced today will not relieve the market before the following planning cycle, so demand is effectively rationed by queue position.

Smaller device companies feel the effect most directly. A start-up with a single product and no in-house manufacturing has limited leverage on booking priority and is often asked to commit to minimum volumes well above its forecast. Some respond by designing for a manufacturing platform that is already qualified, even at the cost of design flexibility, because time to first revenue matters more than an optimised enclosure.

The strategic response among mid-sized OEMs has been partial vertical integration: keeping sterile assembly in-house for flagship products and outsourcing non-sterile subassembly. That preserves control over the highest-risk step while avoiding the capital burden of a second cleanroom. It also keeps the regulatory file simpler, since the sterilisation process remains within a system the company already audits and understands, and it avoids transferring process knowledge to a third party.